Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Martin Reinhold Berger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3783-5365; OpenAlex author ID A5022970757. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 12

  1. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. Co-author DOI 10.1016/j.peptides.2023.171111↗
  2. Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients. Last author DOI 10.1021/acsptsci.3c00013↗
  3. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Last author DOI 10.1016/j.canlet.2020.01.009↗
  4. Lactosyl-sepharose binding proteins from pancreatic cancer cells show differential expression in primary and metastatic organs. Last author DOI 10.1177/1535370220910691↗
  5. Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fphar.2020.549804↗
  6. Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells. Last author DOI 10.1038/s41420-019-0206-2↗
  7. The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment. Last author DOI 10.18632/genesandcancer.173↗
  8. The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Co-author DOI 10.3892/ol.2017.7526↗
  9. Metastasis-related processes show various degrees of activation in different stages of pancreatic cancer rat liver metastasis. Co-author DOI 10.1159/000365496↗
  10. Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Last author DOI 10.4161/cbt.29503↗
  11. Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Co-author DOI 10.3892/or.2012.2049↗
  12. Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/bjc.2011.217↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Micah N. Sagini · 5 shared papers, 2018–2024 · strength 0.84
  2. Ergül Eyol · 4 shared papers, 2011–2024 · strength 0.38
  3. Doaa M. Ali · 2 shared papers, 2019–2024 · strength 0.32
  4. Hassan Adwan · 5 shared papers, 2011–2018 · strength 0.27
  5. Diana Behrens · 1 shared paper, 2024 · strength 0.20
  6. Wolf‐Georg Forssmann · 1 shared paper, 2024 · strength 0.20
  7. Ahmed Murtaja · 2 shared papers, 2014–2018 · strength 0.16
  8. Huiying Huang · 1 shared paper, 2020 · strength 0.13
  9. Khamael K. Al-Taee · 2 shared papers, 2014 · strength 0.11
  10. Jorg H. Kleeff · 2 shared papers, 2011–2012 · strength 0.06
  11. Helmut Frieß · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.